Triple therapy tackles tough lung cancer
NCT ID NCT05403723
First seen Feb 22, 2026 · Last updated Jun 14, 2026 · Updated 20 times
Summary
This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims to see how many patients experience side effects and whether the tumors shrink. About 50 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.